gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:approves
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
gptkbp:availability
|
prescription only
generic available
|
gptkbp:brand
|
Eldepryl
Zelapar
|
gptkbp:casnumber
|
14611-51-9
|
gptkbp:chemical_formula
|
C13 H17 N
|
gptkbp:class
|
phenethylamine derivative
|
gptkbp:clinical_trial
|
depression treatment
Parkinson's disease treatment
|
gptkbp:clinical_use
|
off-label use
adjunct therapy
|
gptkbp:composed_by
|
from phenethylamine
via reductive amination
|
gptkbp:contraindication
|
concurrent use of meperidine
concurrent use of SSRIs
|
gptkbp:developed_by
|
gptkb:Janssen_Pharmaceutica
|
gptkbp:discovered_by
|
1970s
|
gptkbp:duration
|
short-term
long-term
|
gptkbp:excretion
|
urine
|
gptkbp:formulation
|
tablets
orally disintegrating tablets
|
https://www.w3.org/2000/01/rdf-schema#label
|
Selegiline
|
gptkbp:interacts_with
|
antidepressants
tyramine
dopaminergic drugs
|
gptkbp:is_a_guide_for
|
depression management
Parkinson's disease management
|
gptkbp:lifespan
|
10 hours
|
gptkbp:mechanism_of_action
|
MAO-B inhibitor
|
gptkbp:metabolism
|
liver
|
gptkbp:patient_population
|
gptkb:children
adults
elderly
|
gptkbp:pharmacokinetics
|
increases dopamine levels
high bioavailability
well absorbed
|
gptkbp:research_areas
|
gptkb:neurodegenerative_diseases
mental health
|
gptkbp:route_of_administration
|
oral
|
gptkbp:safety_features
|
generally well tolerated
risk of serotonin syndrome
risk of hypertensive crisis
|
gptkbp:side_effect
|
dizziness
nausea
insomnia
dry mouth
|
gptkbp:used_for
|
gptkb:depression
gptkb:neurodegenerative_diseases
|
gptkbp:bfsParent
|
gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
|
gptkbp:bfsLayer
|
7
|